19
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T9927 | Panitumumab | EGFR | |
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR). | |||
T78243 | Human IgG2 kappa, Isotype Control | ||
Human IgG2 kappa Isotype Control is a monoclonal antibody serving as an isotype control specific to human IgG2κ antibodies [1]. | |||
T76779 | Brodalumab | LP 0160,KHK-4827,AMG-827 | IL Receptor |
Brodalumab (AMG 827) is a human monoclonal antibody targeting interleukin 17 receptor (IL-17R) IgG2, often used as an immunosuppressant in the treatment of psoriasis and psoriasis. | |||
T77439 | Glembatumumab | Others | |
Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma.Glembatumumab is a naked antibody to Glembatumumab vedotin and ... | |||
T9920 | Evolocumab | Others | |
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9). | |||
T77491 | Prezalumab | AMG 557 | Others |
Prezalumab (AMG 557) is a human IgG2 monoclonal antibody against ICOSL and BAFF. Prezalumab can be used to study sjogren's syndrome cutaneous lupus erythematosus, psoriasis, systemic lupus erythematosus arthritis and sys... | |||
T76858 | Ascrinvacumab | PF-03446962 | ALK , TGF-beta/Smad |
Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1. Ascrinvacumab has a Kd value of 7 nM for human ALK1. Ascrinvacumab has an inhibitory effect on TGF-β and can be used to study hepa... | |||
T76829 | Tarextumab | ||
Tarextumab (OMP-59R5), a fully human IgG2 monoclonal antibody targeting Notch2/3 receptors, demonstrates anti-tumor activity [1]. | |||
T82367 | Fulranumab | ||
Fulranumab, a human IgG2 monoclonal antibody targeting nerve growth factor (NGF), is utilized in pain research [1]. | |||
T76934 | Brazikumab | ||
Brazikumab (AMG 139), a human IgG2 monoclonal antibody, selectively targets the p19 subunit of IL-23 with a dissociation constant (K D) of 0.138 nM, indicating high affinity for human IL-23. It is employed in Crohn's dis... | |||
T78304 | Bapotulimab | BAY-1905254 | |
Bapotulimab (BAY-1905254) is a fully human IgG2 antibody that targets the immunoglobulin-like domain-containing receptor 2 (ILDR2), exhibiting antitumor and immunosuppressive effects [1]. | |||
T76921 | Befovacimab | ||
Befovacimab (BAY 1093884), a fully human monoclonal IgG2 antibody, binds to the tissue factor pathway inhibitor (TFPI). It is utilized in research for haemophilia A/B [1]. | |||
T76697 | Panitumumab (anti-EGFR) | ||
Panitumumab, a fully human IgG2 anti-EGFR monoclonal antibody, exerts anti-tumor effects by inhibiting tumor cell proliferation, survival, and angiogenesis. It is utilized in researching various cancers, including colon ... | |||
T77173 | Eflepedocokin alfa | ||
Eflepedocokin alfa is a recombinant fusion protein that exhibits cell protective activity by comprising human IL-22 fused with the human IgG2-Fc domain. This compound activates the IL-22/IL-22R -mediated signal transduct... | |||
T78307 | Catumaxomab | ||
Catumaxomab, a trifunctional IgG2 antibody with mouse and rat heavy and light chain components, targets human EpCAM and CD3 receptors. Its Fc region exhibits affinity for FcγRI (CD64), FcγRIIA (CD32a), and FcγRIII (CD16)... | |||
T77450 | Vantictumab | OMP-18R5 | |
Vantictumab (OMP-18R5), a fully human IgG2 monoclonal antibody, antagonizes Wnt pathway signaling through binding to FZD1/2/5/7/8 receptors. It is currently under investigation for the treatment of various cancers, inclu... | |||
T77037 | Insulin efsitora alfa | ||
Insulin efsitora alfa (LY-3209590) is a selective insulin receptor (IR) agonist, comprising a fusion protein that integrates human IR agonists with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2), and ha... | |||
T76791 | Seribantumab | ||
Seribantumab (MM 121), a fully human IgG2 monoclonal antibody, specifically targets HER3, inhibiting the activation of the epidermal growth factor receptor (ErbB) family and its subsequent signaling. This action effectiv... | |||
T76974 | Tafolecimab | ||
Tafolecimab (IBI-306), a human IgG2 monoclonal antibody, specifically targets and binds to PCSK-9, thus inhibiting PCSK-9-mediated endocytosis of the LDL receptor. This action enhances the clearance of LDL-C, resulting i... |